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Epigenetics has been defined as heritable changes in cell phenotypes and 
attendant gene expression patterns that do not directly alter the nucleic acid base 
sequence.  Several interdependent processes are currently classified as epigenetic, such as 
DNA methylation, nuclear positioning and covalent modifications of histone proteins, 
interaction with non-coding RNA species, and higher order organization of nucleic acid 
in the nucleus.  This thesis centers on the activities of key players in maintenance of 
epigenetic imposition of gene silencing, the repressive Polycomb group proteins and 
DNA methylation. Both mechanisms serve as major regulators of normal developmental 
processes and have interactive roles in cancer as potential mediators of abnormal gene 
silencing and associated altered DNA methylation of normally unmethylated regions such 
gene promoter CpG islands.  Our lab has previously reported on the polycomb complex, 
PRC1, and specifically the protein CBX7, and its role in initiating DNA methylation at 
cancer-specific genes in Tera2 embryonal carcinoma cells.  Tera2 has been shown to 
differentiate to neuronal cells in response to exposure to all-trans retinoic acid (ATRA), 
but in CBX7-overexpressing Tera2, a small “outgrowth” subpopulation exhibits retinoid 
resistance after 3 weeks of ATRA exposure.  When withdrawn from ATRA exposure and 
subsequently re-exposed, the majority of Cbx7 outgrowth cells again show sensitivity to 
the differentiating effects of ATRA, but again forms a retinoid resistant subpopulation.  
The CBX7 and CBX7 outgrowth populations exhibit reduced tumorigenicity in 
NOD/SCID mice.  We link CBX7 overexpression to suppression of both canonical and 
non-canonical Wnt signaling pathways, owing in part to transcriptional repression and 
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associated DNA methylation of the LEF1 enhancer protein and cJUN transcription factor.  
In the above Tera2 model, the unresponsiveness of the Wnt pathway induced by CBX7 
may represent an altered epigenetic state associated with a less tumorigenic state with a 
new pattern of cancer-specific promoter CpG island DNA hypermethylation. 
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Epigenetics Overview  
 
Epigenetics has been defined as heritable changes in DNA structure that do not 
directly alter the nucleic acid base sequence (1).  Several processes are currently 
classified as epigenetic, such as DNA methylation, nuclear positioning and covalent 
modifications of histone proteins, interaction with non-coding RNA species, and higher 
order organization of nucleic acid in the nucleus.  These interconnected processes work to 
regulate normal development, differentiation, and responses to environmental stress and 
stimuli, while abnormalities in these systems contribute to cellular dysfunction and 
disease (2). 
 
Histone Modifications and Polycomb Group Proteins 
 
Histone modifications play a major role in epigenetic regulation. Histone core 
octamers- 2 units each of the H2A, H2B, H3, and H4 protein- are encircled by 
approximately 150 base pairs of helical DNA to form nucleosomes (3-5).  The linear 
arrangement of histones along DNA, and their degree of density, correlates with level of 
expression. Regions of DNA with highly condensed nucleosomes correlate with 
heterochromatin, while areas with sparse nucleosomes- open chromatin- are 
transcriptionally competent.  The N-terminal end of histone peptides, often known as 
histone “tails,” extend away from the octamer core.  The side groups of amino acids on 
histone tails are subject to a wide range of covalent modifications, including methylation, 
acetylation, ubiquitination, and phosphorylation (6). The effect of each modification is 
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dependent on the relative position of the modified amino acid in the histone’s peptide 
sequence. The addition and removal of these histone marks are catalyzed by enzyme 
complexes that "write" or "erase" these modifications in a regulated fashions at different 
locations throughout the epigenome (7-9).  
One major histone mark is the acetylation of lysine side chains. Histone 
acetylation is typically found in areas of open chromatin, and often associated with active 
transcription or enhancer elements (10-14). Unmodified lysine residues on histone tails 
counteract the negative charge of phosphate groups in the backbone of DNA. It is 
believed that the addition of neutral acetyl groups eliminates these positive charges, 
making compaction of negatively-charged DNA more difficult (15). Given the need for 
accessible chromatin with transcription, histone acetyltransferases (HAT), most notably 
P300, are often associated with transcriptional co-activators (16-17).  On the other hand, 
removal of acetyl groups by various histone deacetylases (HDACs) is often associated 
with the repression of transcription (18, 19). 
Another major class of modifications is histone lysine methylation. The effects of 
histone methylation are dependent upon both the position of the modified lysine residue, 
as well as the number of methyl groups added to that lysine (20). For example, di and tri-
methylation of lysine 4 of H3 (H3K4) is typically associated with actively transcribed 
genes (21), while H3K4 monomethylation is commonly found at enhancer elements (22, 
23). H3K27 and H3K9 methylation are associated with repressed chromatin (20), but 
methylation of H3 lysine 36 found within the gene body of active genes, promotes 
transcriptional elongation, and blocks abnormal initiation of cryptic transcription within 
genes (24, 25).  The histone lysine methyltransferase and demethylase enzymes are 
4 
 
typically associated with protein complexes that contribute to their recruitment to the 
proper genomic locations, help to refine the specificity of enzymatic action, and facilitate 
the activating or inhibitory functions of the complexes (26, 27).  For example, regulatory 
complexes with repressive effects on transcription can recruit histone lysine demethylases 
that remove modifications associated with active transcription (28), while also 
associating with methyltransferases that catalyze the addition of repressive lysine 
methylation (29-31). 
These histone marks are specifically bound by several proteins with conserved 
protein motifs.  The functional consequences of any of these marks are often defined by 
chromatin-associated proteins that "read" histone modification, i.e. their binding affinity 
with histone tails is altered. For example, proteins with the chromodomain or 
bromodomain protein motif bind methylated lysines or acetylated lysines, respectively (7, 
9, 32).  Minor sequence differences within chromodomain motifs allow a distinction 
between modifications that should lead toward that transcriptional repression versus 
activation of the underlying genetic material (8).  These differences are crucial for the 
divergent effects of active histone methylation, such as H3K4, and repressive marks, such 
as H3K9 and H3K27 (2).  The composition of the protein complexes- including catalytic 
subunits that deposit or remove modification and components that recruit other chromatin 
modifiers- lead to the downstream effects on local epigenetic landscape and gene 
expression. 
In addition to histone tail modifications, the location and density of nucleosomes 
along the DNA molecule has a significant impact on transcription.  Regions of DNA with 
dense, highly-ordered nucleosomes- termed “heterochromatin”- typically have low 
5 
 
expression of the genes encoded in these areas.  In contrast, areas with more sparse 
arrangement of nucleosomes have a greater degree of accessibility for transcription 
factors- termed “euchromatin”- are often associated with genes with higher levels of 
expression (or the greater ability to induce these genes in response to signaling or other 
stimuli) (6).  Proteins that bind repressive histone marks, such as the HP1 family, can 
facilitate the condensation of nucleosomes and drive the formation of heterochromatin (7, 
8).  The recruitment of chromatin-remodeling complexes can also alter the nucleosome 
landscape to either promote or suppress transcriptional activity (13).  Some of these 
remodeling complexes, such as Swi/SNF, require energy in the form of ATP hydrolysis 
to carry out these functions (2, 33). 
The Polycomb group proteins demonstrate a major class of histone modifying 
proteins whose repressive function highlights the critical role for epigenetic regulation 
during development.  The founding member of the group, Polycomb, was discovered as a 
mutant leading to alteration of Drosophila melanogaster body segmentation patterns, 
manifested as in increase in the number of sex combs on the Drosophila leg.  This 
phenotype was attributed to alteration of homeotic gene clusters (Hox genes) responsible 
for anterior-posterior body planning in Drosophila (34).  The various Polycomb proteins 
act in complexes (35), and are typically divided into two groups: Polycomb Repressive 
Complex (PRC) 1 and PRC2.  PRC1 contains Ring1A/B, Ph, Pc/Cbx (homologs of 
dRing, Posterior Sex Combs [Psc], Polyhomeotic [Ph], and Polycomb [Pc]), while PRC2 
contains Ezh2, Eed, Suz12, RbAp48 and RbAp46.  Ezh2 (and Ezh1) of PRC2 contains 
histone methyltransferase activity against lysine 27 of Histone 3 (H3K27), while Ring1B 
contains ubiquitin ligase activity against lysine 119 of Histone 2A (H2A-K119) (36).  
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PRC1 components subsequently bind to the H3K27me3 site via the chromodomain of a 
Polycomb homolog, where it catalyzes the ubiquitination on H2A (36), which might 
interfere with nucleosome position or RNA polymerase function.  Other reports suggest 
that PRC1 can also block transcriptional elongation.  Biochemical data from Drosophila 
also suggests that PRC1 can in fact condense nucleosomes, even in the absence of histone 
tails, suggesting an additional mechanism to promote transcriptional repression (36).  
Both PRC1 and PRC2 associate with HDACs, which also promote chromatin 
condensation and repressive function (37).  A variant of PRC2 – PRC4 – may also 
contain the SirT1 histone deacetylase, and may have different histone targets from the 
PRC2 complex (38).  In vertebrates, several core Polycomb group proteins contain many 
related paralogs, potentially increasing the complexity of regulation achievable by 
different Polycomb complexes (39).  Importantly, Polycomb group proteins have been 
shown to regulate a wide range of developmental regulators in a wide range of organisms 
(29, 40, 41). 
Canonical models of Polycomb-mediated repression state that PRC2 is initially 
recruited to a site of silencing and catalyzes the trimethylation on H3K27 (H3K27me3). 
In Drosophila, a defined consensus DNA sequence – the Polycomb Response Element 
(PRE)- has been shown to play a major role in promoting the recruitment of the 
Polycomb complexes.  While no such sequence has been identified in mammalian cells, 
several other mechanisms have been proposed.  Some DNA motifs within the HoxC 
cluster have been identified as recruiters of Polycomb complexes (42).  One particular 
protein- Polyhomeiotic (Pho) directly binds DNA at a defined sequence (43).  Numerous 
long non-coding RNAs have been demonstrated to bind to PRC2 and PRC1 complexes.  
7 
 
The Xist/Tsix double-stranded RNA contributes to the recruitment of Polycomb 
complexes during random X-inactivation in mammalian female homozygotes (44, 45).  
HOTAIR, an antisense transcript from the mammalian HOXC cluster, binds PRC2 
components Suz12, and facilitates silencing of the HOXD cluster in trans (46, 47).  Other 
long non-coding RNAs, such as ANRIL (at the p16 locus) and MOV10 have been shown 




In mammalian cells, the majority of DNA methylation occurs at the 5-position of 
cytosine bases, most often in the context of 5’-CpG-3’ dinucleotide sequences (51).  This 
reaction is catalyzed by DNA methyltransferase (DNMT) enzymes, which utilize S-
adenosylmethionine as the donor for the methyl group.  In mammalian cells, the primary 
DNMTs are DNMT1 and DNMT3a/b.  DNMT3a and DNMT3b are considered be “de 
novo” methyltransferases, as they have a greater ability to add methyl groups to 
unmethylated CpG dinucleotide targets.  DNMT1 is considered the “maintenance” 
DNMT, as it has far greater methyltransferase activity on hemimethylated CpG sites than 
unmethylated sites (52).  However, additional studies suggest that there is significant 
overlap in maintenance and de novo DNA methylation functions between DNMT1 and 
DNMT3b (53).  CpG dinucleotides are often clustered at or near the promoters of many 
genes- known as “CpG islands” and in repetitive sequences (52, 54).  Most cytosine bases 
within CpG islands are unmethylated, but CpG methylation is found within the open 
reading frame of genes (55).  On the other hand, many repetitive elements (e.g. Long 
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Interspersed Repetitive Elements, LINES) within the human genome contain dense 
methylation and exist within heterochromatin (56).  There is also evidence for non-CpG 
cytosine methylation (e.g. CpHpG, CpHpH, where “H” represents C, A, or T nucleotides) 
in mammalian embryonic stem cells, which is predominantly found in gene exons and 
introns and decreases upon differentiation.  While non-CpG methylation is more common 
in plants (57, 58), the mechanism(s) for maintaining this form of methylation and its 
functional role in stem cells remain to be elucidated (51). 
While DNA methylation has long been considered a highly stable mark over time, 
the discovery of active DNA demethylation and additional covalent modifications of 
cytosine nucleotides has altered our view of DNA methylation.  Most demethylation is 
thought to occur passively, when DNA methylation patterns are not maintained over 
several rounds of DNA replication and cell division.  DNA demethylases, such as 
members of the Ten-Eleven Translocase (TET) family, catalyze the oxidation of 5-methyl 
cytosine, and, to a lesser extent, 5-formylcytosine and 5-carboxylcytosine (59).  It is 
believed that the oxidation products of 5-methylcytosine (5-hydroxymethylcytosine, 5-
formylcytosine, 5-carboxycytosine) are targets of base-excision repair, leading to their 
replacement with an unmodified (unmethylated) cytosine base (60).  In embryonic stem 
cells, TET proteins are enriched at developmental regulators and appear to facilitate 
normal DNA methylation patterns in conjunction with DNMTs (61).  The exact 
mechanisms that promote this repair process and any unique function(s) of these cytosine 
bases with more extensive oxidation are also under intense investigation. 
Despite the wealth of knowledge about DNA methylation, the process(es) that 
initiate aberrant de novo DNA methylation patterns in mammalian cells are an area of 
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active research study.  DNMTs are not considered to have intrinsic sequence specificity. 
In other organisms, non-coding RNA/ double-stranded RNA and histone modifications 
have been causally linked to DNA methylation (52, 57).  Interaction between the histone 
modifications and DNA methylation machinery remains a central theory of the field.  The 
enzyme G9a, which catalyzes the methylation of lysine 9 on histone 3 (H3K9), has been 
shown to promote the recruitment of DNMT3a and 3b during differentiation, linking this 
repressive mark to de novo DNA methylation (62).  Given their importance in the 
repression of developmental regulators, Polycomb group proteins are regarded as playing 
in important role in this process.  Some studies have suggested a role for the PRC2 
catalytic component Ezh2 in recruitment of DNMT1 (63), and additional studies have 
strengthened the link between methylation of H3K27 and DNA methylation (64, 65).  
However, other studies have suggested that additional factors mediate this process (66, 
67).  Ohm et al. have previously shown that genes that are prone to DNA methylation in 
adult cancers are highly enriched for “bivalent” genes, which typically exhibit relatively 
low levels of expression and carry both repressive H3K27 methylation and the active 
H3K4 di and tri-methylation modifications in the vicinity of their transcriptional start site 
(68, 69).  Transcription factors and other developmental regulators are highly enriched 
among bivalent domains, and during the course of differentiation and lineage 
commitment, these regulators resolve into a “monovalent” histone pattern- either 
harboring the active H3K4 methylation pattern alone, or the repressive H3K27 
methylation.  Further studies in our lab have highlighted the tendency for such bivalent 




Epigenetics and Cancer 
 
Epigenetic dysregulation, both with respect to DNA methylation and histone 
modifications, has been shown to play a role in many diseases, most notably in cancer.  
Cancer cells typically exhibit significant shifts in DNA methylation.  Many genes, 
particular tumor suppressors, show increased methylation in CpG islands within promoter 
regions, while showing hypomethylation of CpG dinucleotides in many areas of the 
genome away from CpG islands.  This promoter hypermethylation strongly correlates 
with transcriptional repression of the gene, but only occurs in a small portion of CpG 
islands (2).  In some cases, loss of gene function by promoter hypermethylation in one 
allele is accompanied by genetic abnormalities, such as point mutation or chromosomal 
deletion, of the second allele (55).  While other researchers have highlighted the role of 
prominent “driver” mutations that occur with high frequency in cancer (71), several of 
these genes actually show a frequency of DNA hypermethylation higher than genetic 
defects (72).  However, many defects observed in cancer affect both the genome and 
epigenome.  Hypermethylation of some DNA repair factors promote genomic instability, 
leading to both more genetic abnormalities (73), as well as sensitivity to 
chemotherapeutic agents that generate DNA damage (55, 74).  In addition, some 
mutations directly impact the epigenome, as proteins involved in epigenetic regulations 
are themselves targeted for mutation (75).  Interestingly, neomorphic mutations of the 
Isocitrate Dehydrogenase 1 and 2 (IDH1 and IDH2) enzymes lead to a hypermethylation 
phenotype in leukemia (76).  Mutant IDH1/2 generate 2-hydroxyglutarate instead α-
ketoglutarate, a necessary co-factor for the the enzymatic activity of TET2 and other 
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histone lysine demethylases (26, 76).  These studies link both abnormal active DNA 
demethylation and cellular metabolic abnormalities to the promoter hypermethylation 
observed in cancer and blocks in differentiation.   
Members of our lab have also shown the link between inflammation and promoter 
hypermethylation.  There is a well-known link between chronic inflammation/infections 
and carcinogenesis (77).  In addition to the wide range of viral products that drive cellular 
growth, inflammation also targets the epigenome.  DNA damage is frequently generated 
from reactive oxygen species (ROS) from immune system cells.  O’Hagan et al. were 
able to demonstrate the recruitment of PRC4 components and DNA methyltransferases to 
the site of an induced double-strand break (78).  In response to oxidative damage from 
hydrogen peroxide, there were global shifts in PRC4 members and DNMT1 and 
DNMT3b to GC-rich areas of the genome, with increases in DNA methylation in the 
promoters of genes with low overall levels of expression (79).  Berman et al. have also 
linked the nuclear lamina localization of genes to genome-wide shifts in DNA 
methylation.  Partially methylated domains, which represent large regions of 
hypomethylated DNA with spikes of DNA hypermethylation at CpG islands, show 
significant overlap with lamina-associated domains and regions of DNA that replicate 
later in S phase during mitosis in colorectal cancer cells when compared with normal 
colon (80).   
The role of epigenetics in defining cellular phenotype has taken on renewed 
interest in light of the “cancer stem cell” theory of tumorigenesis.  Traditionally, tumors 
have been thought to emerge as a clonal population as cells sequentially acquire 
mutations.  However, researchers have gained a greater understanding of the 
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contributions of both genetic and epigenetic aberrations to tumor heterogeneity.  In recent 
years, increasing evidence has shown that small subsets of tumor cells – termed “cancer 
stem cells” or “tumor-initiating cells”– were responsible for these properties of tumors 
(81, 82).  Studies on numerous tumors have demonstrated the ability to isolate minor 
subpopulations that are able to regenerate the cellular heterogeneity exhibited by the 
tumor of origin in serial xenograft models (83, 84).  In this sense, they match two 
cardinal features of stem cells – the ability to both self-renew and to differentiate.  
Furthermore, these subpopulations tended to resemble – in expression of embryonic and 
early developmental signaling pathways, morphology, and surface markers (68, 82, 85, 
86) - more primitive and/or undifferentiated cells of that tissue of origin.  This finding led 
researchers to propose that these tumor initiating cells might, in fact, be derived from 
adult stem cells and/or other undifferentiated/primitive cell types through mutations or 
epigenetic alterations. In addition, the “cancer stem cell” theory helped to explain the 
clinical behavior of many tumors (87).  Many chemotherapeutics target cancer cells by 
active cellular processes such as DNA replication or mitosis.  While such drugs could 
destroy terminally differentiated or actively-dividing cells, cancer stem cells may be 
relatively quiescent. Therefore, they would remain less susceptible to such cytotoxic 
agents.  Given their nature as stem cells, they would be capable of differentiation, leading 
to the re-emergence of tumors, as well as self-renewal. 
Despite this evidence, there are still multiple arguments against the “cancer stem 
cell” hypothesis.  Kern et al. highlight the difficulties in identifying and accurately 
measuring the precise proportion of tumor cells within a given tumor, the inaccuracies in 
using surface markers, and tumorigenic potential of “non-stem” cells (88).  In addition, it 
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is usually impossible to isolate truly pure populations of stem cells with commonly used 
markers.  Reduced but measureable levels of tumor formation in “non-stem cell” 
fractions of heterogenous populations suggest that presence of multiple determinants of a 
cell’s ability to form tumors, which may not neatly coincide with the presence of known 
markers (88).   
Dysregulation of the Polycomb group proteins further support the cancer stem cell 
hypothesis.  It is believed that the gene expression changes caused by Polycomb 
dysregulation contribute to the undifferentiated phenotype that is a hallmark of cancer.  
Abnormal control of Polycomb contributes to blocks in differentiation that increase 
tumorigenicity (43), and many individual Polycomb components are overexpressed in 
cancer (89-91).  Along the same lines, other studies have demonstrated the selection of 
drug-resistant populations, facilitated by epigenetic regulators. These cells, in turn, are 
left to regenerate the tumor, ultimately leading to clinical relapse (87) (and references 
therein).  Sharma et al. have demonstrated the development of chemotherapy-resistant 
cell lines (e.g. EGFR and MET kinase inhibitors, RAF inhibitors), which required higher 
levels of the histone demethylase Jarid1A (KDM5A), as well as IGF-1R signaling (92).  
In some cases, these subpopulations were also enriched for the CD133 tumor marker.  As 
previously mentioned, the re-distribution of Polycomb proteins in the context of cellular 
stress appears to increase promoter DNA methylation of susceptible targets, particularly 
those with low levels of expression (79).   
The major contributions of epigenetic regulation of cellular dysfunction represent 
an opportunity for clinical application of drugs that modify the epigenome.  The 
elimination of these stem cells may be achieved by impairing the abnormal epigenetic 
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programs that sustain these subpopulations of cells (87, 93).  Demethylating agents, such 
as the nucleotide analogs 5-aza-cytidine and 5-aza-2’-deoxycytidine (94), have already 
been approved by the FDA for use in treating myelodysplastic syndrome (95).  The 
application of demethylating agents and HDAC inhibitors in solid tumors, either alone or 
as a sensitization agent for other chemotherapies, is already underway (55, 96).  
Exploring how the various systems of epigenetic regulation not only provides greater 
understanding of the dynamic working of cells, but also provides exciting opportunities 





















Abstract (Chapter 2) 
 
 Past research has demonstrated a strong association between histone 
modifications catalyzed by the Polycomb group complexes and cancer-associated DNA 
hypermethylation.  Our previous studies in Tera2 have demonstrated increases in DNA 
methylation with the overexpression of CBX7 in the Tera2 teratocarcinoma cell line.  
Despite cancer-specific patterns of promoter hypermethylation, Tera2 cells with CBX7 
overexpression exhibit resistance to retinoic acid-mediated differentiation, but increased 
latency of subcutaneous tumor formation and decreased frequency of tumor formation.  
We have linked this to promoter hypermethylation and repression of JUN and LEF1, the 
downstream DNA-binding effectors of the canonical and non-canonical Wnt signaling.  
Although we have demonstrated the repression and DNA methylation of CD44, an 
important stem cell marker and transcriptional target, we show that repression of this 
specific target may not be solely responsible for the reduced tumorigenicity.  Lentiviral 
knockdown of CD44 reduces in vitro sphere formation, but does not reduce 
tumorigenicity in xenograft studies.  We hypothesize that other targets of the Wnt 
pathway, or other signaling pathways important for tumorigenicity and/or stem cell 
phenotype, may be responsible for these effects.  However, the unresponsiveness of the 
Wnt pathway induced by CBX7 may represent an altered epigenetic state associated with 








 Despite the long history of research on the Polycomb Group proteins, many 
aspects of Polycomb Repressive Complex (PRC) function remain unclear.  There is 
significant conservation between the Polycomb complexes expressed in Drosophila and 
those found in mammalians cells.  The PRC4 complex as previously been defined as a 
variant of the canonical PRC2 complex.  The PRC4 variant complex has been defined as 
one that contains the SirT1 class III histone deacetylase, as well as novel isoform of the 
Eed accessory protein, which utilizes an alternative translational start site (38).   
 More recently, there have been new discoveries in the role of variations in PRC1 
composition. Gao et al. have shown unique PRC1-like complexes: every complex 
contains Ring1b, which catalyzes the ubiquitination of H2A, but other accessory 
components of PRC1- such as the Polycomb group Ring Fingers (PCGF homologs), 
chromobox (i.e. Cbx) family, and RYBP- bind in a mutually exclusive pattern and 
localize to unique clusters of genes (97).  Among mouse Cbx family members, there are 
also differences in binding affinities to RNA and methyl-lysines (H3K9 and H3K27) 
(98).  Several papers from the Kerpolla lab have demonstrated varying binding affinities 
of Cbx fusion proteins to chromatin (99, 100).  During embryonic stem cell 
differentiation, members of the Cbx family show a mutually-exclusive association with 
core PRC1 members.  In mouse embryonic stem cells, Cbx7 appears to be the 
predominant Cbx member associated with Ring1b, and Cbx7 is localized at the promoters 
of Cbx2, 4, and 8 and represses their expression (101, 102).  When exposed to retinoic 
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acid, these embryonic stem cells differentiate and endogenous Cbx7 expression declines.  
The removal of transcriptional repression by Cbx7 allows a rise in expression in these 
Cbx members.  O’Loghlen et al. (101) highlight the role of miRNA regulation in this 
autoregulatory Cbx system utilized during the differentiation of embryonic stem cells. 
Although these studies have shown unique patterns of recruitment of these variants of the 
canonical PRC1, the exact mechanisms of recruitment and full understanding of their 
functional significance remain to be elucidated. 
 CBX7 was highlighted as a gene that promotes a bypass of replicative senescence 
in prostatic epithelial cells by repression of p16 (103).  Non-coding RNA, ANRIL, and 
H3K27me3 both contribute to the recruitment of CBX7 to the p16 locus (49).  Despite 
this role in suppressing p16, a common target for dysfunction in cancers, there are 
conflicting data on the role of CBX7 in carcinogenesis.  CBX7 accelerates B-cell 
lymphoma formation in the context of c-Myc overexpression, an effect that is dependent 
on p16 repression (104).  Pallente et al. have also shown an association between reduced 
expression of CBX7 in thyroid cancer, and reduced growth with CBX7 overexpression in 
thyroid cancer cell lines (105).  CBX7 expression and recruitment has also been 
demonstrated to increase E-cadherin expression in thyroid cancer (106).  In contrast, 
overexpression of CBX7 in Tera2 embryonal carcinoma cells reduces E-cadherin 
expression and leads to promoter hypermethylation (107). 
 Our lab has previously reported on PRC1 and its role in initiating DNA 
methylation at cancer-specific genes in Tera2 embryonal carcinoma cells (107). The 
Tera2 human embryonal carcinoma cell line is derived from a metastatic testicular tumor.  
Similar to normal embryonic stem cells, Tera2 has been shown to differentiate to 
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neuronal cells in response to exposure to all-trans retinoic acid (ATRA) (108-110).  
However, none of the aforementioned studies on PRC1 combinatory diversity have 
considered changes in DNA methylation.  In addition to the links between PRC2 member 
Ezh2 and its H3K27 methylation mark, PRC1 member CBX7 interacts with the DNA 
methyltransferase 1 (DNMT1), DNMT3a, and DNMT3b and H3K9 methyltransferase 
G9a.  In addition to its role in DNA methylation, overexpression of CBX7 in Tera2 also 
generates a small subpopulation that exhibits resistance to ATRA after several weeks of 
exposure (107).   
 Epigenetic regulation and signaling pathways contribute to normal stem cell 
function and differentiation (41, 82, 111).  The Wingless-Integration site (Wnt) signaling 
pathway represents one such circuit that mediates the balance of stem cell phenotype and 
lineage differentiation.  Members of the LEF/TCF family are constitutively bound to 
DNA at distant enhancer elements, and bind transcriptional co-repressors, such as 
Groucho and HDAC1, in the absence of soluble Wnt ligands.  Long-range chromatin 
interaction between these repressors and transcription factors near transcriptional start 
sites ensure negligible expression of Wnt target genes (23).  Without ligand, the 
transmembrane Wnt receptors LRP and Frizzled do not associate.  The β-catenin 
destruction complex (Glycogen Synthase Kinase 3β [GSK-3β], Axin1, Axin2, Casein 
Kinase) phosphorylates β-catenin.  This phosphorylation event promotes the 
ubiquitination and proteasomal degradation of β-catenin.  The presence of soluble Wnt 
ligand promotes the physical association of Frizzled and LRP, which increases the 
activity of Dishevelled.  The Dishevelled protein destabilizes the destruction complex and 
reduces the kinase activity of GSK-3β, leading to a reduction in β-catenin 
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phosphorylation and an increase in β-catenin protein levels.  Stable β-catenin translocates 
to the nucleus of Wnt-activated cells and binds to LEF/TCF proteins, which displaces co-
repressors from LEF/TCF proteins.  The complex of β-catenin and LEF/TCF recruits 
transcriptional co-activators, which drives Wnt target genes, such as c-Myc and CD44 
(112, 113).   
In addition to this canonical pathway, Wnt ligands have also been shown to drive 
gene expression changes through non-canonical pathway via calcium/Protein Kinase C 
signaling/Cam KII signaling and through activation of Rac/JUN N-terminal kinase (JNK) 
and Rho/ROCK signaling (112).  Phosphorylation of JUN by JNK increases 
transcriptional activity of JUN, and can drive gene expression changes in response to 
numerous stimuli (114, 115).  Unphosphorylated JUN binds HDAC3 and MBD3/NuRD, 
but JNK-mediated phosphorylation reduces the affinity between these co-repressors and 
JUN (116, 117).  However, there is considerable cross-talk between these two branches, 
as JUN can bind to its own promoter (118), and common targets with both AP-1 and 
LEF1/TCF binding sites exhibit increased activity with JUN phosphorylation (112).  This 
interaction of LEF1 and JUN has also been demonstrated for CD44, osteopontin, c-Myc, 
and matrix metalloprotease 7 (MMP7) (119).  Similar to its effect on β-catenin, GSK3β-
mediated phosphorylation of JUN protein facilitates binding of E3 ligase Fbw7 and 
subsequent proteasomal degradation (120, 121). 
Despite extensive research, controversy remains about the role of the Wnt 
signaling pathway in embryonic stem cell regulation.  Wnt signaling has been shown to 
be important for maintaining human embryonic stem cells (122, 123) and in induced 
pluripotent stem cell (iPS cell) formation (124, 125).  On the other hand, numerous 
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papers have demonstrated that inhibition of GSK3β, which increases β-catenin protein 
levels, can promote differentiation of embryonic stem cells (126, 127).  Other studies in 
embryonal carcinoma cells show increases in Wnt activity with retinoid-induced 
differentiation (128).   
To gain greater insight into the consequences of CBX7 overexpression and the 
associated DNA hypermethylation, we performed xenograft studies of our empty vector 
control Tera2, CBX7-overexpressing Tera2, and CBX7 Outgrowth populations.  This 
information was also particularly important given the CBX7-mediated increases in DNA 
methylation in genes commonly methylated in adult cancers (107).  We link CBX7 
overexpression to a suppression of both canonical and non-canonical Wnt signaling 
pathways, owing in part to the repression and DNA methylation of the LEF1 enhancer 
protein and cJUN transcription factor.  These data suggest that Wnt may be important for 







Materials and Methods 
 
Cell Culture. Tera2 cells were cultured in McCoy's 5A (Gibco) supplemented with 15% 
fetal bovine serum (FBS) by volume (Gemini Bio-Products, Atlanta Biologicals).  The 
generation of Tera2 with CBX7 has been previously described (107).  Empty vector, 
CBX7, and CBX7 Outgrowth Tera2 were maintained under constant puromycin 
selection.  All-trans retinoic acid (ATRA) was purchased from Sigma.  Cells were 
exposed to 1uM ATRA, with fresh media added with each splitting of cells or every three 
days.  All cells were grown at 37C in humidified 5% CO2 atmosphere. 
 
Western Blotting.  Whole cell lysates were generated by 30-second vortexing followed 
by 30 minute rotation at 4C in modified RIPA buffer (50mM Tris-HCl, pH 7.5, 150mM 
NaCl, 0.25% SDS) supplemented with Complete protease inhibitor (Roche) and AEBSF 
(Pefabloc, Roche). Cell lysates used for detection of phosphorylated proteins were also 
supplemented with PhosStop phosphatase inhibitor (Roche).  Protein concentrations were 
calculated by BCA protein assay (Pierce Thermo Scientific). 
 
Luciferase Assays.  Tera2 cells were seeded at 25K cells in 24well dishes. Firefly 
luciferase vectors (TOPFLASH/FOPFLASH; Promega) were transfected in a 10:1 mass 
ratio with pTK-RL Renilla luciferase constitutive control vector for normalization 
(Promega). Samples were co-transfected with either β-catenin, LEF1, or with excess 
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pIRES to normalize total DNA transfected. All vectors were transfected with 
Lipofectamine2000 at a 2.5:1 ug DNA:ul ratio (Invitrogen).  Cells were lysed with 
Passive Lysis Buffer (Promega) 48 hours after transfection.  Firefly and Renilla luciferase 
activity in lysates were measured according to Dual Luciferase Reporter Assay System 
(Promega) according to manufacturer's protocol on a Monolight 2010 luminometer 
(Analytic Luminescence Laboratory). 
 
Tumor Sphere Formation.  Tera2 sphere formation was performed as described in 
(129). Cells were dissociated with PBS-based Cell Dissociation buffer. 5000 cells were 
incubated in 1ml of DMEM:F12 supplemented with 10ng/ml EGF (Invitrogen), 20ng/ml 
FGF2 (Invitrogen), and 20ng/µl heparin (StemCell Technologies) in Ultra-Low 
Attachment 24-well Plates (Corning Costar). Cells were seeded on plates without prior 
rehydration of wells. Spheres were counted on day 10 of incubation and photographed on 
AxioCam software. Only spheres larger than 50µm were included in the count. Two 
biological replicates were performed, each performed in quadruplicate. 
 
cDNA Synthesis, Real-time PCR, and Gene Expression Microarray.  Sample mRNA 
was isolated from cell pellets by Qiagen RNeasy kit according to manufacturer's protocol 
(Qiagen) and quantified by NanoDrop. 2µg RNA was digested with DNaseI according to 
manufacturer's protocol (Invitrogen), followed by First-Strand cDNA Synthesis reaction 
(Invitrogen). Real-time PCR reactions were run with Qiagen 2x SYBR Green mix, with 
10nM final primer concentration. PCR reactions were performed on ABI (machine specs) 
with StepOne v2.1 software. Fold changes were calculated by 2-∆∆Ct method, with 
24 
 
normalization to GAPDH. All data represents at least 2 biological replicates, each run in 
triplicate. Primers were ordered from Integrated DNA Technologies. Primer sequences 
are listed in Table 2.1.  Global gene expression studies were performed by Agilent 
Human Gene Expression 4x44K microarray.  Cell pellets for empty vector Tera2, CBX7-
overexpressing Tera2, and CBX7 Outgrowth populations were provided to the Johns 
Hopkins Sidney Kimmel Cancer Center Microarray Core.  RNA isolation and quality 
control was performed by the Microarray Core facility. 
 
Lentiviral Transduction.  Anti-CD44 shRNA lentiviral constructs were purchased from 
Sigma, custom ordered for insertion into the pHGK promoter and neomycin selection 
gene. Twenty-thousand Tera2 cells/well in 24-well plates were seeded, and cells (empty 
vector, CBX7, and CBX7 outgrowth) were transduced at a multiplicity of infection 
(MOI) of 1 with 8µg/ml Polybrene (Sigma).  Media without antibiotics was changed the 
following morning (approximately 16hours). Dual selection (0.5ug/ml puromycin, 
100µg/ml geneticin for empty vector Tera2 and CBX7-overexpressing, 0.5ug/ml 
puromycin, 200ug/ml geneticin for CBX7 Outgrowth) was started on day 2 and 
maintained during all experiments.  Sequences targeted by lentivirus shRNA are listed in 
Table 2.3. 
 
Flow Cytometry.  Samples for flow cytometry were dissociated with Enzyme-free 
dissociation buffer (Invitrogen/Gibco). 5x105 cells were used for each negative control 
and experimental branch. Cells were blocked with 0.5% FBS/PBS for 10 minutes at room 
temperature. Primary antibody diluted in 0.5% FBS/PBS was incubated for 10 minutes at 
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4C. For cell surface staining only, cells were washed with 2ml 1xPBS. For subsequent 
intracellular staining, cells were fixed with freshly prepared 4% formaldehyde (from 
paraformaldehyde powder), permeabilized with 0.2% Triton-X for 10 minutes. For 
unconjugated primary antibodies, cells were then incubated with secondary antibody 
(1:400, 100ul total volume per tube) for 10 minutes at room temperature, washed with 
2ml 1xPBS.  For CD44 staining, unconjugated mouse anti-CD44 (1:10 dilution, Meridian 
Life Sciences) was used as the primary antibody, with 1:400 donkey anti-mouse Alexa 
Fluor 647 secondary antibody.  PerCP-Cy5.5-conjugated anti-Oct4 (BD Biosciences) was 
used for intracellular staining. Samples were analyzed on FACSCalibur flow cytometer 
with FASCComp software (BD Biosciences). 
 
Chromatin Immunoprecipitation.  Chromatin Immunoprecipitation was performed as 
previously described (66). Briefly, actively growing Tera2 cells in 15cm plates were 
rinsed with 1xPBS and cross-linked with 1% formaldehyde in 1xPBS for 10 minutes at 
room temperature, followed by quenching with 125mM glycine. After rinsing, cells were 
dissociated with 0.05mM trypsin for 5 minutes at room temperature, and neutralized with 
10%FBS/1xPBS. Cells were then scrapped and centrifuged. Cell pellets were rinsed 
twice with 1xPBS supplemented with Complete protease inhibitor (Roche) and 1mM 
AEBSF (Pefabloc; Roche). Cytoplasmic extraction was performed by lysis with 
Cytoplasmic Extraction Buffer (CEB: 10mM HEPES Buffer pH 7.8, 10mM KCl, 1.5mM 
MgCl2, 0.34M sucrose, 10% glycerol) with 0.2% NP-40, followed by rinse with CEB 
(without NP-40). Nuclei were resuspended in SDS Lysis Buffer (Millipore) and sonicated 
for 15 pulses of 10 seconds at 2.5 output level, 40% duty cycles, with 20 seconds of 
26 
 
pause between each pulse on a Sonifier 450 (Branson). The sheared nuclei were 
centrifuged at top speed for 10 minutes at room temperature. Chromatin was quantified, 
and master mix of 80ug of chromatin was diluted to 400ul SDS Lysis Buffer, and diluted 
to 4ml in ChIP Dilution Buffer (Millipore). 50µl aliquot (approximately 1ug chromatin) 
of diluted chromatin was stored overnight at -20C as input. Each immunoprecipitation 
was incubated with respective antibodies overnight at 4C on rotator: normal rabbit IgG 
(Upstate), 1µl; anti-HA (Covance), 5µl; DNMT3B (custom antibody, as previously 
described (130)), 0.3ul; DNMT1 (Sigma), 5µl; JUN (Cell Signaling Technologies), 5µl; 
LEF1 (Cell Signaling Technologies), 5µl; H3K4me3 (Upstate), 5µl; H3K27me3 
(Upstate), 5ul; H3 (Abcam), 1.5µl.  5ul Protein A and 15ul Protein G-coated magnetic 
Dynabeads (Dynal/ Invitrogen) were rinsed twice with Blocking Reagent (0.5% 
BSA/1xPBS, Invitrogen) and blocked overnight in fresh Blocking Reagent, rotating 
overnight (approximately 16hrs) at 4C. After incubation, 100ul of blocked magnetic bead 
mixture was added to each immunoprecipitation and incubated at 4C on rotator for 3 
hours. Following incubation, magnetic beads were rinsed four times with Low Salt Buffer 
(Millipore), followed by two rinses with High Salt Buffer (Millipore). Immune 
complexes and beads were incubated with 105ul Elution Buffer (50mM Tris-HCl pH 8.0, 
10mM EDTA, 1% SDS) and heated at 65C for 15 minutes, with vortexing every two 
minutes. Beads were spun for 1minute at maximum speed (~15000g), and supernatant 
was transferred to a new 1.5ml tube. Aliqouted input sample was mixed with 50ul Elution 
buffer. Elutant was incubated overnight at 65C with rotation. The following morning, 
100ul of 1xPBS was added to the samples, and treated with RNaseA (200ug/ml final 
concentration; Amersham) for 1 hour at 37C, followed by 2 hour treatment with 
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Proteinase K (200ug/ml final concentration; Invitrogen) at 55C. DNA was mixed with 
1ml Buffer PB (Qiagen) and loaded on columns on vacuum manifold (Qiagen PCR 
Cleanup Kit), and rinsed with 750ul Buffer PE. DNA was eluted with 2x 50ul Buffer EB 
(Qiagen). All samples were diluted 1:2 in Buffer prior to quantitative real-time PCR. 
Input samples were diluted 1:10 in Buffer EB. 
 
Xenograft Studies.  Cells were trypsinized, counted, and injected 3-5million cells in 
100ul of 1:1 mixture of chilled 1xPBS/MatriGel (Becton Dickinson). NOD/SCID mice 
were injected subcutaneously bilaterally. Tumor incidence was noted at the first palpable 
of subcutaneous tumor. Per protocol guidelines, tumors were dissected when reached 
2cm in any dimension, or when animals exhibited extreme distress.  Dissected tumors 
were sectioned and preserved in 4% formaldehyde overnight.  Fresh 4% formaldehyde 
was prepared by dissolving paraformaldehyde (Sigma) in distilled deionized water.  
Paraformaldehyde was heated to 60C, and depolymerization was catalyzed by addition of 
10ul 1M NaOH in fume hood, and 0.22um filtered.  Tumor fixation into formalin and 
sectioning onto slides was performed at the Johns Hopkins Mouse Phenotyping Core.  
Immunohistochemistry for lineage markers and slide scanning was performed at the 
Johns Hopkins Kimmel Cancer Center Tissue Microarray Core Facility.  Marker 
expression was analyzed by Aperio ImageScope, using the Positive Pixel Count v9 
algorithm.  All studies involving mice were performed according to the rules and ethics 








CBX7 Outgrowth Formation and Tumor Formation in Tera2-CBX7 
 
 Previous research in our lab has shown that Tera2 cells overexpressing CBX7 
differentiate over the course of about three weeks of ATRA exposure.  However, unlike 
empty vector control Tera2 cells, which only express the puromycin selection gene, a 
small subpopulation of CBX7-overexpressing Tera2 cells emerges starting at 
approximately 20 days of exposure to 2uM all-trans retinoic acid (ATRA)- the CBX7 
“Outgrowth” population (107).  This population, which was withdrawn from ATRA 
exposure after 30 days, has been kept continually growing in culture.  When re-exposed 
to ATRA, the CBX7 Outgrowth population once again appears to differentiate in a 
similar manner as Tera2 cells upon their first exposure to ATRA (Figure 2.1).  However, 
upon second exposure to ATRA (at least 5 passages after withdrawal from ATRA), the 
vast majority of CBX7 Outgrowth population differentiated, and once again, a small 
population of retinoid-resistant cells begin to grow after approximately 15 days, a few 
days earlier than CBX7 Tera2 during their first exposure to ATRA.  There are examples 
of retinoid-resistant Tera2 cells caused by genetic defects, such as the loss of retinoic acid 
receptor gamma (RARγ) (131).  However, we believe that the behavior of the CBX7 
Outgrowth population was inconsistent with the selection for a small number of cells 
with genetic defect(s) leading to retinoid resistance, as the majority of cells in the bulk 
CBX7 Outgrowth population would have to revert back to retinoid sensitivity in order to 
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differentiate upon a second exposure to ATRA.  This observation suggested that the 
CBX7 population resembles a “cancer stem cell,” as suggested by a maturation defect in 
the cells and through its ability to regenerate phenotypic heterogeneity (the re-
establishment of ATRA-sensitive cells in the bulk population of CBX7-overexpressing 
cells), and/or other epigenetically defined drug-resistant subpopulations (92, 132).   
 Embryonal carcinoma cells, such as Tera2, are generally believed to be the 
undifferentiated “stem cell” population within malignant testicular cancers (108).  Given 
the existence of a retinoid-resistant subpopulation, we believed that CBX7 
overexpression would accentuate this “cancer stem cell” population(s) and generate 
teratocarcinomas more rapidly and/or with a higher frequency of tumor incidence than 
empty vector Tera2.  Multiple studies have shown that CBX7 has the potential to block 
maturation by repressing transcription factors involved in lineage differentiation (101, 
102).  However, CBX7 Tera2 cells exhibit lower overall frequency of tumor formation 
and higher latency than EF1 tumors, suggesting that CBX7 has tumor-suppressor 
function (Figure 2.2).  Surprisingly, the CBX7 Outgrowth population (generated by Helai 
Mohammad, with one single 30-day exposure to ATRA followed by continued growth in 
ATRA-free media) developed no tumors in NOD/SCID mice. 
One hypothesis for the reduced tumorigenicity in the CBX7-overexpressing cells 
and CBX7 Outgrowth population was that these cells exhibited abnormal differentiation 
potential.  As previously noted, xenografted Tera2 cells can differentiated into all three 
germ layers (endoderm, mesoderm, ectoderm) (108, 110).  Immunohistochemistry (IHC) 
was performed on formalin-fixed sections empty vector Tera2 and CBX7-overexpressing 
Tera2 tumors were examined for a number of lineage markers to evaluate for any change 
30 
 
in the lineages found within the tumors, as represented by the degree of positive staining 
for each marker.  The empty vector and CBX7-overexpression Tera2 showed no 
significant differences in staining for several lineage markers (CD34, CK18, desmin, 
GFAP, chromogranin, S100), which argues against an in vivo shift in differentiation 
potential (Figure 2.3).  Despite the reduced tumorigenicity of CBX7-overexpressing cells 
and the CBX7 Outgrowth population, these cell populations maintained their levels of the 
stem cell transcription factor Oct4 and stem cell marker CD133 in vitro, as measured by 
flow cytometry (Figure 2.4).  Although Tra-1-60, a surface marker of undifferentiated 
embryonic stem cells, showed a reduction in the CBX7 cells, the CBX7 Outgrowth 
population, which formed no xenograft tumors in vivo, had Tra-1-60 levels comparable to 
empty vector controls (Figure 2.4).   
 
Reduction in CD44 and CD44-associated signaling 
 
 Given the reduction in vivo xenograft formation, we hypothesized that CBX7-
overexpressing cells had other gene expression changes, possibly due to promoter DNA 
methylation, that reduce the tumorigenicity of these cells.  We were particularly mindful 
of changes in interaction of the cells with the extracellular matrix (ECM) and in stem cell 
gene programs.  We hypothesized that ECM interactions might be critical for stem cell 
niche interaction and xenograft tumor formation as assayed in vivo, a defect not as 
evident during in vitro 2D cell culture.  Our lab has previously linked cancer-specific 
hypermethylation of ECM targets in colon cancer, albeit such changes could be used to 
predict worse prognosis (72).  In fact, a review of gene expression data from our Tera2-
31 
 
CBX7 system (107) suggested that a number of ECM targets were reduced in the CBX7 
system (Table 2.4).  We found that CD44, a well-known mediator of both cell-ECM 
interaction and stem cell phenotype (133), was significantly reduced by real-time PCR 
and flow cytometry (Figure 2.5).  Both the CBX7 and CBX7 Outgrowth populations 
showed increases in methylation throughout the CD44 CpG island compared to control 
empty vector Tera2 cells (Figure 2.6).  This repression in CD44 could be reactivated with 
short term exposure to the DNA demethylating agent 5'-deoxy-2-azacytidine (DAC- 
72hrs, 1uM; Figure 2.7). In addition to CD44, a number of integrins associated with 
CD44 expression – integrins β1, β2, α7- showed reduction as well (Figure 2.8).  These 
integrins did not show any increase in promoter hypermethylation.  Other integrins, 
however, showed no statistically significant change or modest increases.  Osteopontin, a 
secreted ECM component shown to act in a feedback loop with CD44 and important in 
integrin-related signaling (116, 134), was also reduced (Figure 2.8).  One of the 
downstream targets of CD44 activation, the c-Src kinase, also showed reduced activity 
(as measured by phosphorylation), in the CBX7 and CBX7 Outgrowth populations 
(Figure 2.9). 
In order to detect dysregulated signaling pathways in CBX7 and CBX7 
Outgrowth cells, we performed by MetaCore analysis on global gene expression data 
from Agilent 4x44K gene expression microarray.  This analysis indicated a disruption of 
the Wnt signaling pathway, as CD44, JUN, and LEF1 showed reduced expression in 
CBX7 and CBX7 Outgrowth populations (Figure 2.10).  The role of the Wnt signaling 
pathway in adult cancer has been well demonstrated.  Genetic mutations in colorectal 
cancer, such as mutation of the APC destruction complex member, significantly reduce 
32 
 
the activity of GSK3β and allow increased accumulation of β-catenin protein expression 
irrespective of the presence of Wnt ligand.  In addition, numerous reports have 
demonstrated the epigenetic silencing of inhibitory components of this pathway, such as 
the secreted Frizzled-related proteins and Sox17 (135, 136).  Given this body of 
knowledge, we hypothesized that dysregulation of the Wnt pathway may be relevant to 
the reduction in tumorigenicity exhibited in CBX7-overexpressing Tera2.  Several studies 
have demonstrated the links between Wnt signaling, JUN, and CD44 (137, 138).  We 
confirmed that both JUN and LEF1 mRNA are significantly reduced in CBX7 and CBX7 
Outgrowth cells compared to empty vector EF1 Tera2 cells (Figure 2.11). These changes 
are also observed at the protein level (Figure 2.11). Both LEF1 and JUN show an 
increase in promoter DNA methylation in the CBX7 and CBX7 Outgrowth cells.  The 
CpG island at the LEF1 promoter extends from 1kb upstream from the transcriptional 
start site to 1.5kb downstream.  The downstream portion includes the first exon of LEF1 
and partially into the first intron. Interestingly, the DNA methylation increases do not 
occur at the transcriptional start site, but rises only at the downstream edge of the LEF1 
promoter CpG island (Figure 2.12).  Other members of the LEF/TCF family- TCF1, 
TCF3, and TCF4 (i.e. TCF7L2) showed no change at the mRNA level, and slight 
increases at the protein level (data not shown).  To further evaluate the activity of the 
Wnt/β-catenin signaling pathway, we used the TOPFLASH luciferase reporter system. 
This reporter vector harbors two inverted triplets of multimerized consensus TCF/LEF 
binding sites upstream of a minimal Herpes Simplex Virus (HSV) Thymidine Kinase 
(TK) minimal promoter, which drive expression of the firefly luciferase. The 
FOPFLASH vector, which carries mutated LEF/TCF binding sites, is transfected in place 
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of TOPFLASH as a negative control. In many contexts, the activity of the TOPFLASH 
vector, but not FOPFLASH is enhanced by co-transfection of β-catenin.  As shown in 
Figure 2.13, CBX7 and CBX7 Outgrowth cells show both reduced basal signaling and 
response to co-transfection of β-catenin.  With co-transfection of LEF1 and β-catenin, 
both CBX7 and CBX7 Outgrowth show increases in reporter activity, though still 
significantly less than control Tera2 cells (Figure 2.14).  We used Western blot to 
measure the phosphorylation status of GSK3β, which correlates with the activity of this 
kinase.  We detected no differences in phosphorylation status of the kinase between 
empty vector, CBX7, and CBX7 Outgrowth populations (Figure 2.15) 
 
Chromatin Changes at Wnt Pathway Genes 
 
To further probe this pathway, we used chromatin immunoprecipitation (ChIP) to 
study the localization of CBX7 and DNA methylation machinery.  We have previously 
shown that the recruitment of overexpressed CBX7 to promoters that gain DNA 
methylation (107).  However, we also discovered that repressive complexes, even those 
capable of recruiting DNA methyltransferases, possess the ability to repress gene 
expression even without increases in methylation (139). Consistent with their reduction in 
expression in the CBX7 and CBX7 Outgrowth populations, we found significant 
decreases in the active mark H3K4me3, with modest gains in the repressive mark 
H3K9me3, near the CD44 transcriptional start site (Figure 2.16).  We also detected 
enrichment of DNMT1 and DNMT3B within the gene body of CD44 in areas that also 
show increased DNA methylation (Figure 2.17, Figure 2.18).  There was a loss in active 
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H3K4me3 modification and a decrease in repressive H3K27me3 at the JUN and LEF1 
transcription start sites (Figure 2.19, Figure 2.21).  At JUN, we observed recruitment of 
HA-CBX7 and DNMT1 (in CBX7 Tera2 only; Figure 2.20).  For LEF1, we observed 
HA-CBX7 only in CBX7 cells (not CBX7 Outgrowth), as well as a modest enrichment of 
DNMT1 (Figure 2.22).  We did observe enrichment in DNMT3B in the CBX7 
Outgrowth cells in areas that gained DNA methylation (Figure 2.23). 
 
Validation of CD44 effect in Reduction of Tera2 Tumorigenicity 
 
To validate our findings, we used lentiviral shRNA to knockdown expression of 
CD44. With stable selection (greater than 3 weeks), we were able to confirm reduction in 
CD44 mRNA (Figure 2.24).  Flow cytometry revealed that two of the shRNAs with the 
greatest knockdown (The RNAi Consortium [TRC] #308110 and 296191, labeled as 
shCD44-3 and shCD44-5, respectively) also exhibited reduced expression of surface 
CD44 (Figure 2.25).  Empty vector cells with reduced CD44 produced about 50% fewer 
spheres than empty vector control cells with scrambled-sequence negative control 
lentivirus on in vitro sphere formation ability (Figure 2.26). Though the active shRNA 
constructs all induced an increase in Src phosphorylation, this phosphorylation was 
blunted in the cells with effective CD44 knockdown (shCD44-3) vs. another shRNA that 
was ineffective at reducing CD44 surface expression (TRC #57563, “shCD44-1”; Figure 
2.27). 
Given the results of the in vitro sphere formation assay, we hypothesized that we 
would observe reduced tumorigenicity- i.e. increased tumor latency and/or decreased 
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tumor frequency- in CD44 knock-down cells.  Therefore, we performed a xenograft study 
to assay the tumorigenicity of Tera2 cells transduced with lentivirus with scrambled 
sequence, ineffective CD44 knockdown (shCD44-1), and effective CD44 (shCD44-3).  
Surprisingly, the empty vector Tera2 cells with effective CD44 knockdown showed no 
increase in latency in tumor formation.  In fact, the cell line with ineffective CD44 
knockdown, which had not exhibited any difference in CD44 surface expression, showed 
an increase in latency (Figure 2.28). 
 We attempted to address the role of CD44 with greater knockdown with wild-type 
Tera2 cells.  The previous xenograft experiment required double antibiotic selection: 
puromycin to ensure continued expression of the tagged CBX7-HA construct, and 
geneticin for selection for cells with incorporation of shRNA lentivirus particles.  The use 
of wild-type Tera2 cells, which had not been previously exposed to any antibiotic 
treatment, would allow for high antibiotic concentration for single selection.  
Theoretically, this might allow for selection of cells with that had achieved greater 
knockdown of CD44 (and the accompanying antibiotic resistance gene).  We repeated 
selection for the same panel of lentiviruses with shRNA constructs targeting CD44.  As 
seen in transduction into the empty vector cells, the greatest CD44 knockdown was 
achieved with lentiviruses shCD44-3 and shCD44-5, as measured by mRNA (Figure 
2.29) and by protein levels (Figure 2.30) compared to the non-targeting (negative) control 
(shNTC). 
Upon injection of NOD-SCID with transduced Tera2 cells, surprisingly, neither 
CD44 construct demonstrated a statistically significant change in tumor latency (Figure 
2.31).  However, tumors derived from cells tranduced with shCD44-5 (effective CD44) 
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demonstrated a statistically significant decrease in tumor volume compared to negative 
control cells.  Tumors derived from shCD44-3-transduced cells did not show any 
difference in tumor growth (Figure 2.32).  These divergent results prompted us to 
question the mechanism by which these two lentiviral constructs, which both showed 
similar reductions in CD44 mRNA and surface expression prior to injection in vitro, 
could generate different growth characteristics in vivo.  One hypothesis for the difference 
in behavior between these two lentiviral strains was a difference in the persistence in 
CD44 knockdown between these two constructs.  Once injected, the transduced Tera2 
cells were no longer under antibiotic selection for the anti-CD44 shRNA lentiviral 
constructs.  We compared mRNA expression of CD44 levels at between 9 and 10 weeks 
after injection, a time-point at which xenografted tumors in the non-targeted control and 
shCD44-3 treatment group reached the maximum tumor size permissible under 
institutional rules governing animal experiment protocols (tumor diameter of 2cm).  At 
this time point, both effective CD44 treatments revealed that CD44 knockdown was 
maintained relative to the non-targeting control (Figure 2.33).  In fact, the shCD44-3 
maintained levels of CD44 even lower than shCD44-5.  Therefore, a difference in CD44 








In this study, we were able to demonstrate CBX7-mediated reduction in 
tumorigenicity of Tera2 embryonal carcinoma cell lines. This phenotype emerged despite 
the fact that the protein induces the emergence of a retinoid-resistant population and 
produces cancer-specific patterns of promoter DNA hypermethylation and gene silencing.  
These results extend findings about the cellular response to this cancer-related DNA 
methylation abnormality in terms of the cancer phenotypes associated with such changes. 
Colleagues in the Baylin lab have shown the strong correlation between the 
marking of genes with “bivalent” chromatin in ESC, which are a subset of genes highly 
enriched for transcriptional/developmental regulation, and genes which acquire the above 
abnormal, promoter CpG island DNA methylation in cancer (68, 70).  Notably for the 
present study, key genes which manifested this change, and or had decreased expression 
in cells with CBX7 over-expression, LEF1, cJUN, and CD44, are all listed as bivalent 
genes in human embryonic stem cells.  While Polycomb-marked genes with low basal 
expression may be upregulated, as exemplified by the activation of bivalent genes, this is 
less likely to occur when abnormal DNA methylation is present in the promoter region.  
This latter fact has been well studied for repression of the GATA4 in the Tera2 cells 
versus colon cancer cells (140).  The promoter of this gene is normally bivalently marked 
in Tera2, but without DNA methylation, and the gene is in a poised transcription state 
(140).  Increased expression is readily induced by retinoic acid and the gene assumes an 
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active transcription state by chromatin marking (140). In contrast, when GATA4 is DNA 
hypermethylated in colon cancer cells, basal transcription is fully repressed and tight, 
long-distance chromatin looping envelopes the gene (140).  GATA4 is one of the genes 
which undergoes decreased expression and evolves promoter DNA hypermethylation in 
our initial studies of CBX7 over-expression in Tera2 cells (107).  In these latter studies, 
association of CBX7 and DNMTs appeared to drive the switch from Polycomb-based to 
DNA methylation-based repression.   
 




As alluded to above, we were surprised in our study to find that CBX7 over-
expression induced a less aggressive tumor phenotype despite also inducing a cancer-
specific pattern of DNA methylation abnormalities and gene silencing. In retrospect, our 
observed switches in Tera2 cells for genes with bivalent promoter chromatin and 
Polycomb occupancy to DNA hypermethylation may reflect certain clinical findings in 
some adult cancers.  A cancer cell phenotype has been defined, first in colon cancers and 
later other tumors, termed the CpG Island Methylator Phenotype (CIMP+) (73, 141, 142). 
The CIMP phenotype in colorectal cancer was associated with proximal colon tumors, 
mutations in BRAF, and hypermethylation and silencing of the MLH1 DNA repair 
protein and associated microsatellite instability (MSI) (73, 141, 142).  CIMP+ versus 
CIMP- tumors, including for colon cancer as well as for breast tumors and brain gliomas, 
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are typically associated with a more, rather than less, favorable clinical status (73, 141, 
142-144).  On the other hand, some tumors show worse outcomes for tumors with 
CIMP+ status (145).   
 
Perhaps, then, there are then analogies to phenotypes for certain adult cancers and 
the phenotypes we now observe as a consequence of CBX7 overexpression in Tera2.  In 
the present work, and our previous study (107), CBX7 appears to target a wide range of 
bivalent genes for hypermethylation and to induce a less aggressive tumor phenotype. 
The hypermethylation initiated by CBX7 in embryonal carcinoma cells and the 
mechanisms that direct the establishment of the CIMP+ status may reflect that, in some 
instances, epigenetic abnormalities like promoter DNA hypermethylation can be 
associated with restriction of cell phenotypes to less adept tumorigenic states.  If so, a key 
question is how the methylation changes induced may operate to drive the phenotypes. 
Possibilities inherent to our data are discussed below. 
 
Role of changes in CD44 
 
One change of potential functional importance in our present Tera2 studies 
concerns the DNA hypermethylation and associated silencing of the cell surface protein 
CD44. In considering this, it needs to be discussed that the functions for this protein seem 
to be extremely context dependent.  This single-pass CD44 transmembrane protein is a 
commonly known interactor with the extracellular matrix (ECM) (146).  CD44 is a 
receptor for hyaluronic acid, as well as Osteopontin (OPN; aka Secreted Phosphoprotein, 
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SPP1), collagen, fibrin, and integrins (116).  Association with specific combinations of 
alpha and beta integrins also reinforces the role of crosstalk for CD44 with the 
extracellular environment.  Larger isoforms of CD44, which are included via alternative 
splicing, also contain attachment for heparin sulfate, which has been shown to bind 
various growth factors, such as Fibroblast growth factor (FGFs), epidermal growth 
factors (EGF), and hepatocyte growth factor (HGF)/scatter factor (SF) (116). More 
recently, high expression of CD44 (along with other surface markers) has served as a 
marker of subpopulations of cancer cells with increased tumor-forming potential, termed 
cancer stem cells (CSCs) (133), as determined by tests such as in vitro tumor sphere 
formation and in vivo xenograft assay for both liquid and solid tumors (133, 147-149). 
The well-recognized role for CD44 lends support that this protein helps cancer stem cells 
(and, by proxy, normal adult progenitor cells) maintain protein connections with the 
respective stem cell niche and proper microenvironment, in addition to its role in 
increasing the local concentration of growth factors (133, 150). Further studies of CD44 
have revealed that this protein can also participate in various signaling pathways that may 
also promote an undifferentiated progenitor state (148). In addition to integrin signaling, 
CD44 has been linked to HGF and its signaling through c-Met (133).  Higher molecular 
weight CD44 has also been linked to testicular cancer formation (151).  Overexpression 
of CD44 has also been linked to epithelial-mesenchymal transition (EMT) (152). 
Epithelial cells that have undergone EMT exhibit increased CD44 expression, as well as 
more aggressive and therapy-resistant tumors.  CD44 has also been shown to be a target 
of Wnt/β-catenin signaling (137, 153), and loss of CD44 reduces colon carcinogenesis 




In contrast to the above studies of CD44, our present results associate decreased 
expression of this protein with reduced tumorigenicity. However, as shown in Figure 2.31 
and Figure 2.33, effective and persistent knockdown of CD44 may not be sufficient to 
alter the latency of xenografted Tera2, and, therefore, cannot fully explain the effect of 
CBX7 overexpression on reduced tumorigenicity.  However, our CD44 knockdown 
studies to date with lentivirus shCD44-5 may not be robust enough to induce reduced 
tumor volumes in the mouse studies performed or increased latency for tumor 
appearance. More work will be required to sort out these possibilities. 
 
Role of changes in the Wnt pathway 
 
One of the DNA hypermethylation paradigms in cancer, particularly in colon 
tumors, involves alterations of signaling for the Wnt pathway.  Our lab and others have 
shown epigenetic repression to frequently involve silencing of the secreted Frizzled 
Related Proteins (sFRPs) which are a family of proteins that normally serve as negative 
regulators of the Wnt pathway (107, 135). Also, SOX17, a nuclear protein inhibitor of 
WNT signaling is also very frequently simultaneously silenced (136).   These 
methylation changes are, thus, associated with activation of canonical WNT pathway 
signaling that drives tumorigenesis (135, 136). These epigenetic changes, in colon cancer, 
augment effects of genetic mutation of APC (71) and together inhibit β-catenin 
degradation and force constitutive Wnt activity (135, 136). 
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In contrast to the above activation of the canonical WNT pathway in association 
with abnormal promoter DNA methylation, in our present study, the decreased 
expression of LEF1 and JUN is associated with a constitutive loss of canonical Wnt 
signaling. Importantly, non-canonical WNT signaling is actually associated with cellular 
differentiation and lineage commitment (155-157). Thus, the reduction in tumorigenicity 
may be attributable to the loss of JUN and/or LEF1.  The JUN proto-oncogene was 
originally identified as the human homolog of the avian sarcoma virus v-Jun gene (121).  
JUN is part of the activator-protein 1 (AP-1) complex, which is typically composed of 
members of the Jun family (JUN, JUNB, JUND) and Fos family (FOS, FOSB, FRA1, 
FRA2), and ATF.  Phosphorylation of JUN by members of the JUN N-terminal kinase 
family (JNK) leads to reduced binding of co-repressors (116) and drives increased 
transcriptional activity of the JUN protein.  JNK-mediated phosphorylation also allows 
cells to respond to cellular stress, including DNA damage. Furthermore, JNK signaling 
via JUN also drives the expression of pro-angiogenic factors and ECM modifiers (133).  
In subcutaneous tumor explants, cells are particularly subjected to hypoxia prior to the 
recruitment of murine vessels to the injection site, an effect not observable in in vitro cell 
culture (158).   
We tried to address the potential role of JUN and LEF1 in our Tera2 system by 
lentivirus-mediated shRNA knockdown. For these studies, transduction with anti-LEF1 
and anti-JUN lentiviral shRNA resulted in increased expression in empty vector Tera2 for 
these genes using multiple targeting sequences in independent transduction experiments 
(data not shown).  We did not evaluate whether these changes also occurred in CBX7 and 
CBX7 Outgrowth populations transduced with these constructs, and did not characterize 
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any further cellular changes in these cells.  The mechanism for the increased JUN and 
LEF1 expression in empty vector is not clear, and requires further investigation.   
 
Role of epithelial to mesenchymal transition 
 
Another hypothesis is that the anti-tumorigenic effect of CBX7 is mediated by 
pathways other than Wnt that are aberrantly regulated in CBX7-overexpressing Tera2 
cells.  Notably, our MetaCore analysis revealed that the CBX7 and CBX7 Outgrowth 
populations exhibit genome-wide patterns of TGFβ-dependent Epithelial-Mesenchymal 
Transition (EMT) (Figure 2.35).  EMT represents a spectrum of reversible gene 
expression changes that alters intercellular interactions during the course of normal 
development.  This process generates mesenchymal cells with reduced connections 
between cells and greater mobility, which is essential for the initial stages of 
organogenesis.  Ultimately, the majority of such cells undergo the reciprocal process- 
mesenchymal-to-epithelial transition (MET)- for the formation of the fully-differentiated 
adult organs (159).  EMT requires epigenetic reorganization of large sections of the 
genome, but with no additional changes in DNA methylation (160).  For many adult 
systems, the EMT has been associated with an increase in progenitor/stem cell 
populations, as well as in increase in tumor aggressiveness and/or metastatic potential.  
External signaling, such as via TGF-β, and hypoxia (161), via HIF1α signaling (162), has 
both been shown to drive EMT.  A number of transcription factors, such as Twist1, Snail 
(i.e. SNAI1), Slug (i.e. SNAI2), ZEB1, and ZEB2 (163) are downstream effectors of the 
gene expression programs that drive EMT (161, 162).  These transcription factors serve 
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to repress structural components of adherens junctions, most notably E-cadherin and 
occludins, which are crucial mediators of strong interactions between cells and cell 
polarity.  These factors also drive alterations in gene expression via miRNAs (164, 165) 
and alternative splicing of critical genes (166).  EMT has previously been shown to 
generate cells with increased tumorigenicity (152).   
CBX7 overexpression in Tera2 may show reduced tumorigenicity in part due to 
an Epithelial-Mesenchymal Transition.  Many solid tumors that undergo an EMT are 
thought to select for population with greater tumorigenic potential (152).  Also, adult 
epithelial cells that undergo EMT have been linked to higher expression of CD44 (148, 
152, 167).  On the other hand, embryonic stem cells and other similar pluripotent cells 
(iPS cells, embryonal carcinoma cells) may actually require the close cell-cell interaction 
normally associated with an epithelial phenotype (159, 168).  Embryonic stem cells lose 
this epithelial phenotype as they differentiate and gain mesenchymal characteristics 
during this process (159). During the formation of induced pluripotent stem (iPS) cells, 
cells must undergo a mesenchymal-epithelial transition to return to a pluripotent state 
(169, 170).  Studies on Tera2 from the Baylin lab have previously demonstrated a 
reduction in expression and hypermethylation of E-cadherin with CBX7 overexpression 
(107).  While the majority of cells of xenografted cells ultimately differentiate once 
injected, a small portion must remain undifferentiated to sustain a teratocarcinoma.  If 
CBX7 forces pluripotent embryonal carcinoma cells to undergo an Embryonic-
Mesenchymal Transition, such as due to the loss of E-cadherin or abnormal Wnt 
signaling, these cells may lose the ability to maintain this subpopulation.  Furthermore, 
just as CBX7 leaves Tera2 cells unresponsive to changes in Wnt signaling, CBX7 may 
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restrict cells to a single state with regards to epithelial or mesenchymal phenotype (a 
partial EMT), leaving them unable to perform a dynamic process of either EMT or MET 
(159).  As discussed by Nieto (159), the cancer stem cells from adult tumors may not 
need to reach an epithelial-like phenotype characteristic of embryonic stem cells/iPS 
cells.  This may explain why EMT reduces tumorigenicity in Tera2 cells, while 
increasing tumorigenicity in many other adult cancers. 
Morphologically, CBX7 and CBX7 Outgrowth cells appear to have a more 
fibroblast-like appearance, a common hallmark of EMT (Figure 2.1).  In addition, there is 
preliminary evidence that CBX7 and CBX7 Outgrowth exhibit greater mobility than 
empty vector cells as determined by in vitro scratch test (data not shown).  Given the 
importance of the EMT process, additional study of this pathway in Tera2 and 
perturbations caused by CBX7 expression into the potential links of Polycomb repression 




 As previously stated, our results have led us to the conclusion that the increased 
DNA methylation initiated by Cbx7 overexpression in Tera2 reflects the formation of a 
less tumorigenic state, despite induction of widespread promoter hypermethylation.  
Many of the cellular changes that occur during carcinogenesis- the “Hallmarks of 
Cancer”- represent a shift to a restricted state of autonomous and uncontrolled cell 
growth and lack of responsiveness to external signals (171, 172).  Promoter 
hypermethylation is viewed as one the central mechanisms that promotes such 
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tumorigenic states, e.g. by inactivating tumor suppressors that allow constitutively active 
Wnt pathway (135).  However, as we have discussed, promoter hypermethylation 
associated with the CpG Island Methylator Phenotype (CIMP) in many solid tumors, 
including breast, gastric and colorectal cancer, suggests alternative consequences of this 
mechanism of gene silencing.  The Wnt and EMT pathways allow cellular plasticity, 
leading to global changes in gene expression, cellular behavior, intercellular interaction, 
and differentiation.  While many cancers direct these pathways into a restricted and active 
state, the reduced tumorigenicity observed in embryonal carcinoma cells with Cbx7 
overexpression demonstrates that these tumorigenic pathways could also be reduced in 
certain contexts.  At the level of chromatin, embryonic stem cells have relatively open 
chromatin and require a dynamic turnover of chromatin proteins (173).  Cbx7 
overexpression may not only stabilize protein complexes that contain DNA 
methyltransferases, leading to the observed hypermethylation (107), but may also prevent 
this open chromatin conformation that maintains stem cell expression and pluripotency 
and allows full developmental potential (173).  This could explain why embryonal 
carcinoma cells, like embryonic stem cells, might be particularly susceptible to 
restrictions on plasticity. 
The ability to distinguish scenarios where epigenetic changes accelerate 
tumorigenecity from those where the consequences may be a less aggressive cancer state 
is of great clinical significance. There is currently an increasing interest in the concept of 
epigenetic therapies for a wide range of solid tumors (174).  Future research will require a 
greater understanding of the mechanisms that correlate hypermethylation signatures to 
changes in the aggressiveness of individual tumors.  If the reduced tumorigenicity in 
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CIMP+ tumors indicates that there are other mechanisms other than promoter 
hypermethylation that drive individual tumor types, inducing DNA demethylation may 
have minimal impact on a patient’s clinical course.  Research by the Baylin lab has 
shown the ability for long-term benefit in a cohort of patients extensively treated with 
other chemotherapy agents after short-term epigenetic therapy with a combination of 
HDAC inhibitors and DNA demethylating agents (96).  While some patients showed 
remarkable responses to epigenetic therapy, others exhibited stable disease or progressive 
disease.  Ongoing research is required in order to distinguish which patients would most 
benefit from epigenetic therapy.  In cases where promoter hypermethylation limits the 
tumorigenic potential of cancer, the administration of demethylating agents could allow 
the re-expression of genes that promote tumor progression or reduces tumor cell 
responsiveness to other treatments (175).  For some patients, targeting Polycomb-
mediated repression (or components of the epigenetic machinery) might represent a better 
strategy. 
Ongoing research in cancer strongly suggests that the heterogeneity of tumors for 
properties such as metastatic ability and/or chemotherapy resistance, as well as the ability 
of cancer cells to regenerate that heterogeneity, makes the eradication of cancer a difficult 
challenge.  This principle has already been demonstrated in vivo for drug-tolerant states, 
which can be re-sensitized with small molecule inhibitors (92).  While we were able to 
manipulate Polycomb genes via direct transfection, developing clinically applicable 
methods that restrict the phenotypes into less tumorigenic or less metastatic states by 
altering the function of Polycomb group proteins may represent a major mode of 
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treatment for cancer. In this regard, potent new inhibitors of Polycomb action have 
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Tables and Table Legends 
 
Gene Primer Sequence (5'->3')
CD44 Forward AGCCTGGCGCAGATCGATTTGA
Reverse GGCCTCCGTCCGAGAGATGC















Reverse ATTGGTCTCTCCCGGCTGCTTGTC  
 




































Set 7R TGGGCAGTTAGAGAGAAGGTGA  
 



















Set 7R TTTCCCGCTTCGCGGAGA  
 






Label TRC ID Sequence (5’  3’) 
shCD44-1 57563 CCGGGCCCTATTAGTGATTTCCAAACTCGAGTTTGGAAATCACTAATAGGGCTTTTTG 
shCD44-2 289308 CCGGCGCTATGTCCAGAAAGGAGAACTCGAGTTCTCCTTTCTGGACATAGCGTTTTTG 
shCD44-3 308110 CCGGCCGTTGGAAACATAACCATTACTCGAGTAATGGTTATGTTTCCAACGGTTTTTG 
shCD44-4 289233 CCGGCCTCCCAGTATGACACATATTCTCGAGAATATGTGTCATACTGGGAGGTTTTTG 
shCD44-5 296191 CCGGGGACCAATTACCATAACTATTCTCGAGAATAGTTATGGTAATTGGTCCTTTTTG 
 


















Table 2.4: Extracellular Matrix proteins with reduced expression in Cbx7-
overexpressing Tera2.  Gene expression differences between empty vector control 
and Cbx7-overexpressing Tera2 were measured by Agilent Gene Expression 
microarray data, as described previously by Mohammad et al. {{137}}.  “All down” 
represents genes downregulated in Cbx7-overexpressing Tera2 relative to empty 
vector control.  “CpG” denotes genes with CpG island-containing promoters, as 
determined by UCSC criteria. 
 
All Down CpG PcG All Down CpG PcG
CD44 CD44 CD44 ICAM1 ICAM1 ICAM1
CDH1 CDH1 CDH1 IGFBP2 IGFBP2 IGFBP2
CDH11 CDH11 CDH11 IGFBP7 IGFBP7 IGFBP7
COL1A1 COL1A1 LAMA1 LAMA1
COL2A1 COL2A1 COL2A1 LAMA5 LAMA5
COL3A1 LAMB1 LAMB1 LAMB1
COL4A1 COL4A1 LAMB3
COL4A2 COL4A2 LAMC1 LAMC1
COL4A5 COL4A5 LOX LOX LOX
COL4A6 COL4A6 LOXL1 LOXL1
COL5A1 COL5A1 LOXL3 LOXL3
COL5A2 LOXL4 LOXL4
COL8A1 COL8A1 MMP2 MMP2 MMP2
COL11A1 MMP11 MMP11
COL12A1 COL12A1 COL12A1 NID1 NID1
COL16A1 NTN1 NTN1 NTN1
COL27A1 COL27A1 COL27A1 NTN4 NTN4 NTN4
EVL PLAU PLAU
FBN2 FBN2 FBN2 SDC2 SDC2 SDC2
FBN1 FBN1 FBN1 TGFB2 TGFB2 TGFB2
FLNC FLNC THBS1 THBS1 THBS1
FN1 FN1 THBS3 THBS3









Figure 2.1: Formation of retinoid-resistant Cbx7-overexpressing Tera2 and Tera2 
Cbx7 Outgrowth cells.  Empty vector, Cbx7 Tera2, Cbx7 Outgrowth Tera2 were 
exposed to all-trans retinoic acid (ATRA).  Cells were shown at Day 15, and Day 30 of 






Figure 2.2: Tumor formation in empty-vector control Tera2, Cbx7-overexpressing 
Tera2 and ATRA-exposed Cbx7 Outgrowth population.  5 million cells were injected 
subcutaneously in NOD/SCID mice 1:1 with MatriGel (100ul volume).  Empty Vector 
EF1, Cbx7-overexpressing Tera2, and retinoid-exposed Cbx7 Outgrowth Tera2.  Y-axis 
value represents tumor-free survival; each decrease represents time of first detection of 
palpable subcutaneous tumors in xenografted animals.  Data represents totals from three 







Figure 2.3: Immunohistochemistry for lineage markers on xenografted empty 
vector, Cbx7, and Cbx7 Outgrowth Tera2 teratocarcinomas.  IHC image for EF1 
(top panel), Cbx7 (middle panel) and comparison of positive staining in empty vector 
Tera2 xenograft and Cbx7-overexpressing Tera2 (bottom panel) for markers CD34, 
CK18, Desmin, GFAP, Chromogranin, S100.  Xenografted mice were sacrificed 
when subcutaneous tumors reached 2cm in size, according to animal protocol 







Figure 2.3 (cont.)  IHC image for EF1 (top panel), Cbx7 (middle panel) and comparison 
of positive staining in empty vector Tera2 xenograft and Cbx7-overexpressing Tera2 







Figure 2.5: Validation of microarray results for loss of CD44 mRNA and protein.  
Real-time quantitative PCR was used to measure levels of CD44 in empty vector, Cbx7, 
and Cbx7 Outgrowth cells.  Flow cytometry with anti-CD44 and conjugated secondary 







Figure 2.6: Increase in DNA methylation at the CD44 promoter.  Promoter DNA 
methylation was measured by Illumina Infinium 450K microarray with empty vector, 
Cbx7, and Cbx7 Outgrowth cells.  X-axis shows location relative to the CD44 








Figure 2.7: Re-expression of CD44 with 1uM demethylating agent 2’-deoxy-5-
azacytidine (DAC, decitabine).  72 hour treatment of empty vector, Cbx7, and Cbx7 
Outgrowth cells with 1uM DAC (fresh media with DAC changed at 24-hour intervals).  
Cells were incubated with primary rabbit anti-CD44 antibody and anti-rabbit APC-
conjugated secondary or anti-rabbit APC-conjugated antibody only (Isotype) prior to 
























Figure 2.9: Measurement of c-Src total expression and phosphorylation status.  










Figure 2.10 MetaCore Analysis on gene expression comparison of empty vector, 
Cbx7-overexpressing Tera2, and Cbx7 Outgrowth populations.  Agilent Gene 
expression microarray data comparison of empty vector vs. Cbx7 (thermometer 1) and 
Empty vector vs. Cbx7 Outgrowth populations (thermometer 2) were analyzed via 







Figure 2.11: Validation of reduction in LEF1 and cJUN DNA binding proteins.  
Comparison of LEF1 and cJUN mRNA expression levels were measured by cDNA 
synthesis followed by real-time PCR.  Immunoblots were used to confirm reductions in 








Figure 2.12: Analysis of CpG DNA methylation at LEF1 and cJUN genomic loci by 
microarray.  Global methylation analysis was performed by Illumina Infinim450K array 
for LEF1 (A) and JUN (B).  Values along the X-axis represent location relative to gene 
transcriptional start site.  Y-axis values represent beta values.  Dark bars below the X-axis 






Figure 2.13: Study of Wnt pathway analysis by TOPFLASH LEF/TCF reporter 
assay.  Empty vector, Cbx7, and Cbx7 Outgrowth populations were co-transfected with 
b-catenin, pRL-TK constitutive Renilla luciferase control and either the TOPFLASH 
(WT consensus LEF/TCF binding sites) or FOPFLASH (mutant LEF/TCF binding sites) 
Photinus firefly luciferase reporter vectors.  Cell lysates were analyzed for luciferase 







Figure 2.14: Luciferase reporter constructs with co-transfection with LEF1.  Empty 
vector, Cbx7, and Cbx7 Outgrowth populations were co-transfected with TOPFLASH 
and LEF1, b-catenin, or both.  Cell lysates were analyzed for luciferase activity after 48 














Figure 2.15: Protein expression and activity status of Glycogen Synthase Kinase 
(GSK)-3β.  Immunoblotting was used to measure total expression levels of GSK3β, as 











Figure 2.16: Chromatin immunoprecipitation (ChIP) of H3K4me3 at the CD44 
transcriptional start site.  ChIP for H3K4me3, associated with active genes, and 
repressive histone marks H3K9me2 were performed at the CD44 transcriptional start 









Figure 2.17: Recruitment of HA-Cbx7 and DNMT1 to the CD44 CpG island within 
gene body.  ChIP using anti-HA was used to show recruitment of the tagged Cbx7 
protein at genes that gain CpG DNA methylation.  Enrichment values relative to non-
immunoprecipitated input were calculated by real-time PCR.  Primers used for ChIP are 







Figure 2.18: Recruitment of DNMT3 to the CD44 CpG island within gene body.  
ChIP using anti-HA was used to show recruitment of the tagged Cbx7 protein at genes 
that gain CpG DNA methylation.  Enrichment values relative to non-immunoprecipitated 









Figure 2.19: Chromatin immunoprecipitation (ChIP) of H3K4me3 and H3K9me3 at 
the JUN locus.  ChIP for H3K4me3, associated with active genes, and repressive histone 








Figure 2.20: Recruitment of HA-Cbx7 and DNMT1 near the JUN CpG island 
promoter.  ChIP using anti-HA was used to show recruitment of the tagged Cbx7 protein 
at genes that gain CpG DNA methylation.  Enrichment values relative to non-
immunoprecipitated input were calculated by real-time PCR.  Primers used for ChIP are 










Figure 2.21: Chromatin immunoprecipitation (ChIP) of H3K4me3 at the LEF1 
transcriptional start site.  ChIP for H3K4me3, associated with active genes, and 








Figure 2.22: Recruitment of HA-Cbx7 and DNMT1 in the LEF1 CpG island gene 
body.  ChIP using anti-HA was used to show recruitment of the tagged Cbx7 protein at 
genes that gain CpG DNA methylation.  Enrichment values relative to non-
immunoprecipitated input were calculated by real-time PCR.  Primers used for ChIP are 









Figure 2.23: Recruitment of DNMT3b LEF1 CpG island within gene body.  ChIP 
using anti-HA was used to show recruitment of the tagged Cbx7 protein at genes that 
gain CpG DNA methylation.  Enrichment values relative to non-immunoprecipitated 








Figure 2.24: Short-hairpin RNA-mediated reduction in CD44 levels.  Empty vector 
cells were transduced with lentivirus particles carrying anti-CD44 shRNA sequences or 
scrambled sequence (“NTC”).  Transduced cells were placed under dual selection for 
puromycin (for Cbx7-HA selection) and geneticin (for stably-transduced cells).  For each 
shRNA sequence, real-time PCR was performed after approximately 2 weeks after 






Figure 2.25: Flow cytometry of lentiviral mediated knockdown of CD44.  Empty 
vector, Cbx7, and Cbx7 Outgrowth were transduced with lentivirus particles carrying 
anti-CD44 shRNA sequences.  Transduced cells were placed under dual selection for 
puromycin (for Cbx7-HA selection) and geneticin (for stably-transduced cells).  Flow 









Figure 2.28: Xenografts of EF1, Cbx7, and Cbx7 Outgrowth with CD44 lentiviral 
knockdown.  EF1, Cbx7, and Cbx7 Outgrowth were transduced with non-targeting 
control shNTC, shCD44-1 (ineffective CD44 knockdown) or shCD44-3 (effective CD44 







Figure 2.29: Short-hairpin RNA-mediated reduction in CD44 levels in WT Tera2.  
Wild-type Tera2 cells were transduced with lentivirus particles carrying anti-CD44 
shRNA sequences.  Transduced cells were placed under single selection for geneticin (for 
stably-transduced cells).  For each shRNA sequence, real-time PCR was performed after 
approximately 2 weeks after transduction.  Sequences targeted by lentiviral cconstructs 







Figure 2.30: Flow cytometry of lentiviral mediated knockdown of CD44.  Wild-type 
Tera2 cells were transduced with lentivirus particles carrying anti-CD44 shRNA 
sequences.  Transduced cells were placed under single antibiotic selection for geneticin 
(for stably-transduced cells).  Flow cytometry was used to validate reduction in surface 






Figure 2.31: Xenografts of WT Tera2 with CD44 lentiviral knockdown.  Wild-Type 
Tera2 cells were transduced with non-targeting control shRNA sequence (shNTC) or 
anti-CD44 shRNA (shCD44-5 or shCD44-3, both effective CD44 protein knockdown), 









Figure 2.32: Xenografts of WT Tera2 with CD44 lentiviral knockdown.  WT Tera2 
were transduced with non-targeting control shRNA sequence or anti-CD44 shRNA 
(shCD44-3 or shCD44-5, both of which demonstrate effective CD44 knockdown), 
followed by selection for stable clones with geneticin.  A.) Average tumor volume (in 







Figure 2.34: Expression levels of integrins in CD44-knockdown empty-vector Tera2 
cells.  Real-time PCR for osteopontin and integrin β1 in empty vector cells transduced 
with non-targeting control (shNTC) or anti-CD44 shRNA lentivirus followed by long-






Figure 2.35: MetaCore analysis on gene expression changes in Cbx7 and Cbx7 
Outgrowth populations.  Orange bars represent comparison of empty vector to Cbx7-
overexpressing Tera2 cells, while blue bars represent the comparison of empty vector to 
Cbx7 Outgrowth populations.  Gene expression changes were based on Agilent Gene 
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